Everolimus and Octreotide in a Patient with High-Grade Pancreatic Neuroendocrine Carcinoma

Context Peritoneal dissemination is an important prognostic factor for patients with metastatic pancreatic adenocarcinoma. For an improved prognosis and quality of life, more effective treatment for ascites is necessary. Case report We describe a seventy-oneyear-old Japanese man with pancreatic adenocarcinoma with malignant ascites who had responded to treatment with Nab-paclitaxel plus gemcitabine after novel cell-free and concentrated ascites reinfusion therapy. For ascites control, keisuke matsusaki cell-free and concentrated ascites reinfusion therapy was performed twice. After that, systemic chemotherapy was initiated. His performance status improved since keisuke matsusaki cell-free and concentrated ascites reinfusion therapy could control the refractory ascites, which allowed chemotherapy to be administered. As a result, the patient survived for 11 months and was able to live without hospitalization for most of this time. Conclusion Keisuke Matsusaki cell-free and concentrated ascites reinfusion therapy may be an effective treatment for refractory ascites associated with cancerous peritonitis of pancreatic adenocarcinoma. Received July 21st, 2017 Accepted September 04th, 2017